Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Testing Dispatch

Medutest result on a Xianning survodutide lot lands 4.4 points above the supplier’s stated figure

The report states the gradient, the wavelength and the integration threshold, which is more than most.

Two laboratories analysing vials from the same survodutide lot have returned figures 4.4 percentage points apart. Medutest reported 97.1%; PeptideMeter reported a lower number on a shallower gradient with a tighter integration threshold. Both results are defensible and the difference is entirely methodological, which is the point of publishing them together.

Content by elemental nitrogen determination returned 96% of the labelled nominal mass, which on a 30 mg vial corresponds to roughly 13.75 mg of peptide rather than the labelled figure. The remainder is accounted for by counter-ion, residual water and residual solvent, none of which is visible chromatographically.

The wider context is that material sold for research use carries no regulatory release specification in any jurisdiction the Journal has examined. A certificate is a commercial document, not a compliance one, and its content is whatever the issuer chooses to put on it. That is the gap independent testing fills, and it fills it imperfectly.

"Content is the number that matters if you are doing arithmetic with a vial, and content is the number nobody sells," said Havel Novotný, independent laboratory quality manager. "Purity is what you can afford. Content is what you need."

Homopeptide’s dossier has been updated with this determination and with the company’s response to it. The dossier’s ordering box records the lead times, the minimum quantities and what a buyer should ask for at the point of order.

Related coverage